ENCAINIDE HYDROCHLORIDE

Description

Encainide is an oral and injectable antiarrhythmic structurally related to flecainide. It is reportedly useful in the treatment of symptomatic and life-threatening ventricular arrhythmias. While it appears to have higher efficacy than quinine, the morbidity and mortality rates are comparable.

Originator

Bristol-Myers (USA)

The Uses of ENCAINIDE HYDROCHLORIDE

Cardiac depressant (anti-arrhythmic.

Definition

ChEBI: The hydrochloride salt of encainide. A class Ic antiarrhythmic, it was used for the treatment of severe or life-threatening ventricular arrhythmias, but it was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalitie after a recent heart attack and was withdrawn from the market.

Manufacturing Process

Encainide was prepared in three steps starting with methylantranylate.
A solution of 529.8 g (3.505 mole) methyl anthranilate and 294.4 g 50 weight percent NaOH (3.68 mole) in 3.6 L CH2Cl2 and 1.8 L water was stirred in an ice-bath as 627.8 g (3.680 mole) p-anisoyl chloride was added at such rate that the temperature did not exceed 10°C (time required was 1.25 hr). The mixture was allowed to warm to 23°C. Acetic acid (50 mL) was added to adjust the pH to 5. The layers were separated and the organic layer was washed with 10% aqueous NaHCO3 (1 times 0.8 L) and brine (1 times 0.8 L). The residual white solid was recrystallized from 7.0 L boiling material. The product was dried in vacuo at 70°C for 24 hr to yield 959.7 g (96.0%) white crystalline solid, melting point 122.5°C-124.5°C.
2-(2-Pyridylacetyl)-p-anilsanilide. A dry, nitrogen purged flask was charged with 1.875 ml 1.6 N (3.0 mole) n-butyl lithium in hexane. The solution was stirred under nitrogen and chilled to -45° to -40°C, and 1.5 L THF (dried over molecular sieve 4 A) was added slowly. Diisopropylamine (303.6 g; 3.0 mole) was added at such a rate that the temperature did not exceed -30°C. Then 307.3 g (3.3 mole) 2-picoline was added with stirring, keeping the temperature below -30°C. The cooling was interrupted, and the mixture was slowly warmed to 10°C by which time the conversion to anion was complete and all the 2-picolyl lithium had redissolved. The solution was recooled to - 45°C to -40°C (the orange solid reprecipitated), and a solution of 285.3 g (1.0 mole) methyl N-p-anisoylanthranilate in 1.9 L dry THF was added at a rate so the temperature did not exceed -30°C. After the addition, the mixture was slowly warmed to 25°C. The solution was adjusted to pH 6 with 500 mL acetic acid; 5.0 H2O was added with stirring. Then the organic solvents were distilled in vacuo and the residual yellow semi-solid product was extracted with CH2Cl2 (1 times 2.5 L). The extract was washed with H2O (1 times 1.0 L) and stripped to dryness in vacuo. The residue was dissolved in 6.7 L boiling isopropanol. The solution was chilled with stirring to 5°C, and the resulting yellow solid was collected on a filter, rinsed with isopropanol and dried in vacuo at 80°C for six hours. The filtrate was concentrated and chilled to yield a second crop of product. Both crops of intensely yellow material exhibited single spots in the TLC (7.5 cm silica gel with indicator, 9 CH2Cl2/1 methanol, UV). The total yield was 306.7 g (88.5%) of material, m.p 145°-148.5°C.
2-(2-Pyridylacetyl)-p-anisanilide (25.0 g, 0.0722 mole) was dissolved withgentle warming in 500 ml THF. The bright yellow solution was chilled in an ice bath, and 6.5 ml (0.078 mole) 12 N HCl was added. The yellow color disappeared and a white precipitate formed immediately. The solid was collected on a filter; rinsed with THF and air-dried to give 27.4 g white solid 2-(2-pyridylacetyl)-p-anisanilide hydrochloride (99.3%), m.p. 190.5°-191.5°C. (dec.).
4-Methoxy-2'-[2-(1-methyl-2-piperidyl)-ethyl]benzanilide, Encainide. A mixture of 53.5 (0.1397 mole) 2-(2-pyridylacetyl)-p-anisanilide hydrochloride, 1.0 g platinum catalyst (2.5-5% Pt/C or PtO2) and 1.0 L glacial acetic acid was stirred vigorously under a slight positive pressure of H2 at 23°-25°C for 20 hr, by which time 0.43 mole (3.08 equivalents) of H2O had been absorbed. The catalyst was removed by filtration through a celite bed. The filtrate was returned to the flask, and 10.0 g 10% Pd/C was added under nitrogen. The mixture was stirred vigorously under H2 as it was heated to 60°C. After an additional 6.5 hr the total H2 uptake equaled 0.71 mole (5.08 equivalents, 101.6% of theory). The mixture was cooled to 25°C, and 22.7 g formalin (37 weight percent formaldehyde, 8.4 g, 0.28 mole) was injected into the reaction mixture. The mixture was stirred vigorously under H2 at 23°-25°C for 20 hr; during that time 0.1452 mole (1.04 equivalents) H2 was absorbed. The catalyst was removed by filtration, and the filtrate concentrated in vacuo to a thick oil. Twice the oil was mixed with 200 mL isopropanol and stripped in vacuo at 90°C to a thick oil. The oil was dissolved in 200 mL boiling isopropanol. The solution was stirred, seeded with, and chilled to 10°C for 1 hr. The solid was collected on a filter, rinsed with cold isopropanol (2 times 2.0 mL) to give 36.6 g (67.4%) product, m.p. 181.5°-184.5°C. Additional product was obtained from isopropanol filtrate to give a total yield of 76.1% encainide.

brand name

Enkaid (Bristol Labs).

Therapeutic Function

Antiarrhythmic

Biochem/physiol Actions

Encainide hydrochloride is a sodium channel blocker and class Ic antiarrhythmic. Encainide is a non-chiral antiarrhythmic and benzanilide derivative.